Guest guest Posted June 18, 2003 Report Share Posted June 18, 2003 Encouraging results for Copernicus' non-viral gene transfer system to correct defect in CF Copernicus Therapeutics presented data at the 6th Annual Meeting of the American Society of Gene Therapy, held from 4th to 8th June, in Washington DC, showing that its compacted DNA formulation partially restored chloride channel function in the nasal epithelial cells of human subjects with cystic fibrosis (CF). No serious adverse events occurred in the trial, demonstrating that the compacted DNA nanoparticles could be safely administered to the nostrils of CF subjects. This Phase I/II trial was a joint collaboration of Copernicus, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, The Children's Hospital of Denver and Cystic Fibrosis Foundation Therapeutics. A recently completed clinical trial in CF subjects indicates that the DNA drug was safe and well tolerated when applied to the nasal mucosa, and encouraging gene transfer endpoints were observed. Two-thirds of the trial subjects demonstrated evidence of DNA expression, with partial correction of the underlying chloride channel defect that is responsible for CF disease manifestations. Becki YOUR FAVORITE LilGooberGirl YOUNGLUNG EMAIL SUPPORT LIST www.topica.com/lists/younglung Pediatric Interstitial Lung Disease Society http://groups.yahoo.com/group/InterstitialLung_Kids/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.